Neuroblastoma

Retinoid Fenretinide Squashes Tumor Proliferation In Separate Pathways

Published in Cancer Weekly, December 4th, 2001

by Sonia Nichols, senior medical writer - Fenretinide, currently undergoing clinical investigation for the treatment of cancer, appears to inhibit endothelial cell-related angiogenesis using two separate pathways.

Several investigations of fenretinide, a retinoid, are now underway in order to establish its efficacy for treating solid tumors. The authors of an Italian study have announced fenretinide (HPR) attacks neuroblastoma-stimulated angiogenesis and endothelial cell proliferation by means of direct and indirect approaches.

"HPR inhibited vascular endothelial growth factor (VEGF-) and fibroblast growth factor-2-(FGF-2)-induced endothelial cell...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-12-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry